The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity. This strategic move positions Globus to further add to ...

BTIG lowered the firm’s price target on Globus Medical (GMED) to $88 from $94 and keeps a Buy rating on the shares as part of a broader ...

Globus Medical GMED has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

In the preceding three months, 5 analysts have released ratings for Globus Medical GMED, presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ...

(MENAFN- GlobeNewsWire - Nasdaq) AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93. The company’s 50 day moving average price is $83.16 and its 200 day moving average price is $79.92.

If you’re on the fence about investing in Globus Medical, Inc. or Integer Holdings Corporation because you’re not sure how ...

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed ...